Business Context and Reporting Period
This Form 6-K filing by Bioblast Pharma Ltd. (also referred to as Enlivex Ltd. in metadata) covers the month of December 2018. The filing serves to notify shareholders of an amendment to the date of the Annual and Extraordinary General Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
The primary material change disclosed is the rescheduling of the Annual and Extraordinary General Meeting of Shareholders. The meeting was originally scheduled for December 26, 2018, and has been rescheduled to December 27, 2018. The agenda and the record date (November 26, 2018) remain unchanged.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on business performance. The meeting is convened to approve resolutions required to consummate a merger and other transactions, though specific details of the merger are not elaborated in this text. No specific risks or contingencies are detailed beyond the procedural nature of the meeting reschedule.
Key Facts for Investor Verification
- The Annual and Extraordinary General Meeting is now scheduled for December 27, 2018.
- The record date for voting eligibility remains November 26, 2018.
- Shareholders of record on the record date are entitled to vote on resolutions regarding a merger and other transactions.
- The filing incorporates by reference the Amended Notice of Meeting, Proxy Statement, and Proxy Card.
- The registrant is Bioblast Pharma Ltd., with Dr. Dalia Megiddo serving as Interim Chief Executive Officer.